Oxford Genome Sciences, Medarex to collaborate on cancer treatments

By E. Janene Geiss

Philadelphia, May 10 - Oxford Genome Sciences Ltd. and Medarex, Inc. announced Wednesday that they have entered into a strategic collaboration to discover and develop new human antibody therapeutics for the treatment of cancers, including colorectal cancer.

The collaboration combines Oxford's ability to discover novel targets for oncology with Medarex's expertise in the development of fully human antibody therapeutics, according to a company news release.

The collaboration provides for Oxford and Medarex to discover, develop and commercialize therapeutic antibodies on a 50:50 basis, officials said. Other financial terms of the agreement were not disclosed.

During the initial phase of the collaboration, Oxford said it intends to provide novel colorectal cancer targets, against which Medarex expects to generate fully human monoclonal antibodies using its proprietary UltiMAb Human Antibody Development System.

Oxford said it plans to utilize its unique Oxford Genome Anatomy Project database, a human protein database that integrates genomic, proteomic and clinical information derived from blood and tissue studies for a large number of diseases from 50 different human tissues and representing 60 diseases.

Oxford is an Oxford, England, biopharmaceutical company focused on the development of personalized medicines, mainly for oncology.

Medarex is a Princeton, N.J., biopharmaceutical company focused on fully human antibody-based therapeutics to treat cancer, inflammation, autoimmune disorders and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.